Quoin Reports Statistically Significant Interim Netherton Data, Announces Up to $50 Million Financing

Four of six patients met the primary endpoint at Week 12, while results showed improvement across multiple clinical measures. A concurrent institutional financing could extend Quoin’s runway into the second half of 2029.

Quoin Pharmaceuticals (NASDAQ: QNRX) entered August 28 with two significant developments for its lead program in Netherton Syndrome: positive interim results from its ongoing Phase 2/3 study of QRX003, an investigational topical serine protease inhibitor lotion, and a private placement financing of up to approximately $50 million.

Together, the announcements strengthen both sides of Quoin’s development story. The first provides statistically significant interim clinical evidence from QRX003. The second would provide approximately $30.8 million in upfront funding, with the potential for another approximately $19.2 million through the exercise of accompanying warrants, giving the company additional capital as it advances the program toward a full topline readout expected in the second quarter of 2027.

Statistically Significant Results at Week 12

The interim analysis covers the first six patients to complete 12 weeks of treatment in CL-QRX003-004, Quoin’s Phase 2/3 study of QRX003 4% lotion in Netherton Syndrome.

Four of six patients, or 66.7%, achieved the study’s primary endpoint of at least a one-grade improvement from baseline in Investigator Global Assessment across the treatment area at Week 12. The result produced a p-value of 0.0087, meeting the pre-specified alpha-adjusted threshold of 0.0215 for the interim analysis.

Two of the four responders achieved an improvement of two grades or greater.

The study also met a key secondary endpoint. The Global Statistical Test of Global Impression of Change reached statistical significance at Week 12 with a p-value of 0.0070, also below the pre-specified interim alpha threshold.

Importantly, the improvement was not limited to a single clinical measure.

The same four patients who met the primary IGA endpoint also recorded clinically meaningful improvement on the Ichthyosis Area and Severity Index, or IASI, with reductions in disease severity ranging from 31% to 87% from baseline. The results provide consistency across two separate clinician-assessed measures of skin disease.

Itch, among the most burdensome symptoms associated with Netherton Syndrome, also showed improvement. All three patients who entered the study with moderate-to-severe pruritus achieved at least a three-grade improvement on the Worst Itch Numeric Rating Scale after 12 weeks of QRX003 treatment. One patient improved by more than six grades.

The results also come in an important treatment context. Under the study protocol, patients discontinue all standard-of-care therapy, including topical and systemic prescriptions, for the duration of the study. The Week 12 findings therefore reflect outcomes recorded while patients were receiving QRX003 without those other treatments.

On safety, Quoin reported no treatment-related serious adverse events and no clinically significant ECG, laboratory or vital-sign abnormalities in the interim cohort.

Capital to Advance the Program

Alongside the clinical results, Quoin announced a private placement with new and existing healthcare-focused institutional investors for up to approximately $50 million in gross proceeds.

The financing includes approximately $30.8 million upfront through the issuance of 6,305,300 American Depositary Shares, or pre-funded warrants in lieu thereof, together with accompanying ordinary warrants. Those warrants could provide up to an additional approximately $19.2 million if exercised for cash by investors.

Participants include Sirenia Capital Management, Sphera Healthcare, AIGH Capital Management, Nantahala Capital, StemPoint Capital and Stonepine Capital Management, among others, as well as members of Quoin’s management team and Board of Directors.

Leerink Partners is serving as lead placement agent, with BTIG and Lake Street Capital Markets acting as co-placement agents.

One element of the financing structure directly connects the warrants to the progress of CL-QRX003-004. The warrants are immediately exercisable and expire on the earlier of five years after closing or 30 days following Quoin’s public announcement that the primary endpoint has been met in the trial.

The placement is expected to close on or about August 31, 2026. Assuming the cash exercise of all accompanying warrants, Quoin expects the aggregate net proceeds to fund the company into the second half of 2029.

That would leave Quoin funded for more than two years past the completion of CL-QRX003-004, assuming full exercise.

Market Response

Investors responded immediately. Quoin shares opened at $7.22 against a prior close of $5.16 and traded as high as $8.25, changing hands near $6.08 in late morning.

Volume told the clearer story. More than 27 million shares changed hands by late morning against a trailing average near 238,000, over one hundred times normal turnover.

The Next Readout

Quoin expects to complete enrollment of all 20 participants in CL-QRX003-004 by the end of 2026 and report topline data in the second quarter of 2027.

The interim data provide several encouraging signals heading into that readout: the primary endpoint met its pre-specified statistical threshold, a key secondary endpoint did the same, the same patients showed improvement across two clinician-assessed skin measures, and patients entering the study with the most significant itch also recorded clinically meaningful improvement.

The regulatory foundation for the program is already established. QRX003 has received Orphan Drug, Rare Pediatric Disease and Fast Track designations from the U.S. Food and Drug Administration, as well as Orphan Drug Designation in the European Union and Japan.

There are currently no treatments approved specifically for Netherton Syndrome in the United States. Quoin has said that QRX003, if approved, could become the first.

With enrollment expected to conclude by year-end, full study results targeted for the second quarter of 2027 and additional capital committed, Quoin enters the next stage of QRX003’s development with both positive interim evidence and a substantially strengthened financial position.